News Archive

ReproUnion researchers defended their PhD projects virtually in 2020

Jan 18, 2021

Fostering the next generation of researchers is vital to meet the future demands of managing and preventing infertility problems. In 2015-18 ReproUnion supported 24 research projects and here we feature Selma Kløve Landersø and Pernille Udesen, who were among the first to virtually defend their PhDs during the COVID-19 pandemic. They were closely followed by Sacha Stormlund and her Freeze-all strategy in ART project, as well as Kristina Wendelboe Olsen, whose PhD revealed novel insights to the understanding of female reproductive ageing.

Epigenetic Biomarkers of Metabolic Syndrome in women with Polycystic Ovary Syndrome
By Pernille Udesen, Zealand University Hospital, who defended her PhD on 27 May 2020.

Polycystic ovary syndrome (PCOS) is the largest endocrine disorder of reproductive aged women. Women with PCOS have, beside reproductive challenges, a threefold increased prevalence of metabolic syndrome (MetS) compared with weight-matched controls and many will develop type 2 diabetes (T2D).
Despite these facts and because screening strategies vary substantially between guidelines there is no consensus of how this increased risk should be managed. Since screening of all women with PCOS is not applicable, there is a demand for biomarkers to stratify the risk of women with PCOS.

This PhD-project set out to explore the epigenetics of PCOS to find possible markers or predictors of MetS and T2D and thereby predict, which of the women with PCOS would develop severe metabolic disease.

Pernille investigated the possibilities of microRNA and DNA-methylation as predictive biomarkers and at her PhD defence she commented how a possible microRNA biomarker had been identified, which is a very interesting, important, and promising result.

There were three distinct parts of the study:

– Study I and II were based on a 6-year follow-up study of 46 women with PCOS and nine controls and a cross sectional validation study of 140 women with PCOS and 29 controls. Parred serum samples were used both for analysis of 96 selected microRNAs and for digital droplet qPCR to estimate the number of demethylated and methylated copies of INScfDNA – a possible marker of Beta-cell loss. The cross-sectional study with analysis of 24 selected microRNAs was used to validate the findings in the first part of the study.

– Study III was based on a study of 65 women with PCOS, who were randomized to three treatment groups (metformin, oral contraceptive pills or a combination) for 12 months. In this study 24 microRNAs were analysed in paired serum samples.

Pernille concluded that miR-122-5p is a promising, most likely non-PCOS specific, biomarker for MetS, whereas methylated INScfDNA probably has limited use in predicting metabolic risk factors such as prediabetes. Further, that miR-122-5p reflects the clinical state of the women and possibly also their metabolic hepatic health.

In April 2019 ‘Reproductive Biology and Endocrinology’ published the article:
Levels of circulating insulin cell-free DNA in women with polycystic ovary syndrome – a longitudinal cohort study

In November 2020 ‘Endocrine Connections’ published the article:
Metformin decreases miR-122, miR-223 and miR-29a in women with polycystic ovary syndrome

Academic Advisors:

Main supervisors on the PhD project were associate prof., Anne Lis Mikkelsen Englund;
Prof. Louise Torp Dalgaard and PhD Marie Louise Muff Wissing.

Ovarian Reserve Assessment during Use of Hormonal Contraceptives
By Selma Kløve Landersø, Rigshospitalet, who defended her PhD on 3 June 2020.

Correct interpretation of ovarian reserve markers is crucial in the counselling of women in terms of family planning. Assessment of the markers is challenged during use of the combined oral contraceptive pill, since use of the pill artificially changes the levels of the markers, thus hampering the interpretation of the results.

Selma conducted several cohort studies investigating 1) when the levels of the ovarian reserve markers normalize after discontinuation of the contraceptive pill, 2) whether the ovarian reserve markers were similarly affected by use of other types of hormonal contraceptives.

In collaboration with The Fertility Assessment and Counselling Clinics at Rigshospitalet, Herlev Hospital and Hvidovre Hospital, Selma and her colleagues found the following results: After discontinuation of the contraceptive pill, the ovarian reserve markers normalized within two months and could thereafter be measured reliably again. Further, they found that the markers were also decreased among users of the progestin-only pill and partly the desorgestrel containing intrauterine device. Thus, cautious interpretation should be made in case of particularly the very low levels of the ovarian reserve markers since it is not possible to differentiate the effect of the hormonal contraception from a condition of a diminished ovarian reserve. Last, in an epidemiological study, Selma and colleagues showed that many women are concerned, whether use of the contraceptive pill impair their fertility and that this is causing women to discontinue. However, this concern is scientifically unfounded, and past users of the contraceptive pill have equal fertility rates one year after discontinuation as non-users.

In 2020 Reproductive Biomedicine Online published the article:
Ovarian reserve markers after discontinuing long-term use of combined oral contraceptives

In 2019 the European Journal of Contraception & Reproductive Health Care published the article:
Ovarian reserve markers in women using various hormonal contraceptives as well as
Concerns on future fertility among users and past-users of combined oral contraceptives: a questionnaire survey

Academic Advisors:

Main supervisors on the PhD project were prof. Anders Nyboe Andersen, prof. Henriette Svarre Nielsen, PhD, MD Kathrine Birch Petersen, PhD, MD Elisabeth Clare Larsen.

It’s a couple issue!

At the Women's health network meeting: "Driving innovation and empowerment to improve women´s health", arranged by Hologic, Inc. and Medicon Valley Alliance, Lærke Priskorn, Researcher at Department of Growth and Reproduction, Rigshospitalet was one of four Nordic...

read more